Skip to content

Alumis Inc. ALMS Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Amgen logo
AmgenAMGN
1.3×+0.1×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
23.8×-6.3×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
8.9×-12.7×
Vera Therapeutics logo
Vera TherapeuticsVERA
13.6×-14.0×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
29.3×+13.3×

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on the most recent quarter.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s current ratio?
Alumis Inc. (ALMS) reported current ratio of 7.5× in Q1 2026.
How has Alumis Inc.'s current ratio changed year-over-year?
Alumis Inc.'s current ratio increased by 101.3% year-over-year, from 3.7× to 7.5×.
What is the long-term trend for Alumis Inc.'s current ratio?
Over 2 years (2023 to 2025), Alumis Inc.'s current ratio has grown at a 30.3% compound annual growth rate (CAGR), from 2.6× to 4.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.